Whereas target-specific medication can be found for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailor-made remedy exists for hormone receptor- and ERBB2-negative (“triple-negative”) mammary carcinomas. Triple-negative tumors account for 15% of all breast cancers and often harbor defects in Read more…